Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, October 10, 2017
Protea Biosciences announced it plans to develop clinical screening assays in various areas of oncology.
read more
Celerion has announced the multimillion-dollar expansion of specialized pharmacies across their clinical research units in North America.
read more
Tuesday, February 18, 2014
Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract
development and manufacturing organization (CDMO) specializing in small molecule APIs, has
announced the hire Alex Tretyakov, Ph.D. as its Director of Process Development.
read more
Catalent has signed an agreement with ViralClear to work on the development of a potential treatment for adults with advanced COVID-19.
read more
Wednesday, September 25, 2019
Catalent and Minerva Neurosciences have entered into a commercial supply agreement for roluperidone, an investigational compound from Minerva, for symptoms of schizophrenia.
read more
Catalent has signed an agreement with Cybin to apply Catalent’s proprietary Zydis ODT technology for the delivery of Cybin’s novel deuterated tryptamine.
read more
Catalent announced a multi-year $350 million investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across ...
read more
Humanigen has dosed the first COVID-19 patient in its study for lenzilumab, the company’s GM-CSF monoclonal antibody.
read more
Tuesday, December 10, 2019
Catalent has completed clinical production of Bridge Therapeutics’ opioid addiction development therapeutic product, BT-219.
read more
Catalent welcomed the announcement by Biohaven the FDA has approved its NURTEC™ ODT for acute migraine in adults.
read more
Thursday, January 23, 2020
Catalent supports the news that DiaMedica received FDA approval to commence Phase 2 clinical trials of DM199 for chronic kidney disease.
read more
Thursday, February 27, 2020
Catalent announced the FDA has approved AYVAKIT for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor.
read more
Friday, December 05, 2014
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement...
read more
Thursday, September 22, 2022
Catalent, a leader in enabling biopharma, cell, gene, and consumer health partners to optimize the development, launch, and supply of better patient treatments across multiple modalities, announced that it has reached an agreement to acquire Metrics ...
read more
Cascade Chemistry has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9.
read more